Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Milestone Pharmaceuticals (MIST) announced the first European patient has been enrolled in its Phase 3 ReVeRA-301 trial for etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, targeting 150 patients, is evaluating the same 70 mg dose approved for PSVT in the U.S. as CARDAMYST. Enrollment is ongoing in the U.S. and Canada.
How this was made
The 30-second read
Why it matters
The European enrollment expands the trial's geographic scope, potentially accelerating data readout and supporting a future sNDA submission.
Market read
First European patient enrollment is a material, first‑report event for a small‑cap biotech, likely to generate modest positive price movement.
What to watch
Regulatory timeline for the supplemental NDA and competitive landscape of AFib‑RVR treatments could limit upside.
Background
Milestone Pharmaceuticals (Nasdaq: MIST) is developing etripamil nasal spray for acute atrial fibrillation with rapid ventricular rate. The company previously received FDA approval for the same formulation in paroxysmal supraventricular tachycardia.
Ticker impact
Milestone Pharmaceuticals announced the first European patient enrollment in its Phase 3 ReVeRA-301 trial for etripamil nasal spray.
modest upside as investors price in advancing trial data
First European enrollment is a fresh, material development for a small‑cap biotech; no prior public disclosure.
Market effects
Positive signal for the cardiovascular biotech sector as trial progress may lift peer valuations.
European investors may show increased interest in the trial sites and related CROs.
Adds to the pipeline narrative for US‑listed biotech firms developing arrhythmia therapies.
Counterpoint
If the trial faces enrollment delays or safety issues, the stock could face pressure despite the milestone.
Key entities
- companyMilestone Pharmaceuticals Inc.
Biopharma focused on cardiovascular medicines, ticker MIST.
- organizationDutch Cardiovascular Investigator Network (WCN)
European clinical trial site network enrolling the first patient.
